Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations and Communications. Please go ahead. Good morning, and thank you for joining UMORA Therapeutics' fourth quarter and full year 2024 Financial Results Conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me on the call are Numora's Chief Executive Officer, Paul Burns, President, Josh Pinto, Chief Operating and Development Officer, Bill Arora, and Chief Financial Officer, Mike Milligan. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details. With that, I'll now turn the call over to Paul. Thanks, Helen. Good morning, everyone, and thank you for joining us to review our fourth quarter and full year 2024 financial results and business update. As you may know, I've recently taken over as CEO And I'm pleased to be here with all of you today. I have been fortunate to have had multiple experiences leading teams to drive the successful development and approval of medicines. And I believe Numora has the potential to achieve this outcome as well. The first two months of 2025 have been productive for the co...